About

ZOMIG

ZOMIG provides speed, power, and versatility across 3 formulations that are proven to provide clinical efficacy.

This section provides important data about all 3 formulations of ZOMIG. You will see how each formulation treats migraine headaches with speed, power, and versatility to bring the migraine relief your patients need.

The Speed: FAST HEADACHE RESPONSE

All 3 formulations of ZOMIG have the speed to provide rapid migraine relief.

The Power: PAIN-FREE RESPONSE

All 3 formulations of ZOMIG have the power to deliver a pain-free response by reducing migraine pain from severe or moderate in intensity to a state of no pain.

The Versatility: FORMULATION OPTIONS

ZOMIG has the versatility of multiple administration options that will accommodate virtually any migraine treatment program or patient preference.

Indication and Important Safety Considerations

ZOMIG is indicated for the acute treatment of migraine with or without aura in adults, where a clear diagnosis of migraine has been established.

ZOMIG is not intended for the prophylactic therapy of migraine and is not indicated for the treatment of cluster headache.

ZOMIG is contraindicated in patients with
- Ischemic heart disease (eg, silent ischemia, angina), coronary artery vasospasm, or other significant underlying cardiovascular disease
- Cerebrovascular syndromes (eg, history of stroke or TIA)
- Peripheral vascular disease (eg, ischemic bowel disease)
- Uncontrolled hypertension
Use of ZOMIG is contraindicated within 24 hours of another 5-HT₁ agonist, ergotamine-containing or ergot-type medication, or within 2 weeks of an MAO-A inhibitor
ZOMIG should not be administered to patients with hemiplegic or basilar migraine
It is strongly recommended that ZOMIG not be given to patients in whom unrecognized coronary artery disease (CAD) is predicted by the presence of risk factors without a satisfactory cardiac evaluation
Patients with symptomatic Wolff-Parkinson-White syndrome or arrhythmias associated with other accessory cardiac conduction pathways should not receive ZOMIG
Development of potentially life-threatening serotonin syndrome may occur with triptans particularly during combined use with selective serotonin reuptake inhibitors (SSRIs) or serotonin norepinephrine reuptake inhibitors (SNRIs)
Phenylketonuric patients should be informed that ZOMIG-ZMT^® (zolmitriptan) contains phenylalanine
ZOMIG should only be used during pregnancy if the potential benefit justifies the potential risk to the fetus
Most common adverse reactions in clinical trials for ZOMIG and ZOMIG-ZMT were paresthesia, asthenia, nausea, dizziness, pain, chest or neck tightness or heaviness, somnolence, and warm sensation
Most common adverse reactions in clinical trials for ZOMIG Nasal Spray were unusual taste, paresthesia, hyperesthesia, and dizziness

ZOMIG and ZOMIG-ZMT are registered trademarks of the AstraZeneca group of companies. This product information is intended for US health care professionals only.

This product information is intended for
US health care professionals only.